Choongki Min

Choongki Min

Auto-generated profile, based on publicly available information

Choongki Min

AI Medtech R&D, Waycen Inc., Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2025 in JMIR Formative Research
Verified
Journal Article
Open access
YKYujin Ko
Yujin Ko
JLJeemin Lee
Jeemin Lee
KHKyunghee Ham
Kyunghee Ham
YCYesol Cho
Yesol Cho
YSYu-Bin Shin
Yu-Bin Shin
Jae-Jin KimJae-Jin Kim
Jae-Jin Kim
Background: Panic disorder is characterized by sudden panic attacks and persistent anticipatory anxiety. While pharmacotherapy remains effective, patients with panic disorder often experience residual symptoms and functional impairments. Lifestyle factors influence symptom severity but are often unaddressed in routine psychiatric care. Most current digital therapeutics for panic disorder have a limited scope, lack integration with clinicians, and fail to consider behavioral patterns. To address these limitations, our research team developed a prescription-based app that supports structured cognitive behavioral therapy practice, real-life symptom management, and lifestyle modifications for patients with panic disorder, and a management console—a web-based platform that allows clinicians to monitor the patients’ engagement and progress as well as determine therapeutic options if necessary. Objective: This study aimed to test the usability of the app and management console by evaluating their interface, functionality, and user experience. The primary goal was to identify the strengths and areas for further improvement of these software devices and to develop a list of modifications to improve the user experience and clinical applicability in updates to refine the devices for a future clinical trial. Methods: Usability data were collected by investigators at a medical device usability research center without the involvement of the development research team, and the participants were 15 patients with panic disorder and 15 psychiatrists. Each group completed experimental use of the app or management console and scored the convenience and safety of its modules, questionnaire evaluations for the acceptability, and presentation of verbal subjective feedback on areas for improvement. Based on the participants’ suggestions, a list of items that need to be modified to improve functionality and ease of use for each device was created. Results: Patients completed 155 assigned tasks for the app with more than 98% success, and psychiatrists completed 34 tasks for the management console with more than 86% success. The convenience and safety scores for the app and management console exceeded the neutral threshold (mean >4.5). For all statements about the acceptability, both patients and psychiatrists responded at the level of agreeing with a score exceeding 3 (mean: 3.6~4.3 and 4~4.7, respectively). There were 38 suggestions for app improvements and 66 suggestions for management console improvements, most of which were incorporated in the modification list. Conclusions: Patients reported that the app might be easy to use and help manage anxiety, and psychiatrists found the management console practical and well-suited for outpatients. By combining patient-facing therapeutic tools with clinician-driven prescription and monitoring, the devices offer a solution aligned with clinically integrated, real-world psychiatric care. Modified devices based on the improvement suggestions presented in this study will be evaluated in future clinical trials for their impact on engagement and treatment outcomes.

22 September 2025 in JMIR Preprints
Verified
Preprint
Open access
PKPyung Kim
Pyung Kim
JJJooYi Jung
JooYi Jung
CMChoongki Min
Choongki Min
DKDohyeong Kim
Dohyeong Kim
JHJeongeun Hwang
Jeongeun Hwang
DSDae Jin Song
Dae Jin Song
BACKGROUND Fine particulate matter (PM2.5) is a major trigger of pediatric asthma exacerbations, yet individual sensitivity varies considerably. Existing interventions often adopt a uniform approach, despite this heterogeneity. OBJECTIVE This study aimed to evaluate the feasibility and effectiveness of a pilot mobile health (mHealth) intervention that integrates personal PM2.5 monitoring, deep learning (DL)–based prediction and tailored behavioral recommendations to mitigate exacerbation risks in children. METHODS In this 3-year pilot study, 272 pediatric patients with asthma were enrolled across nine tertiary hospitals in Korea. Using asthma symptom reports and personal PM monitoring data collected via smartphones and portable devices, a 1D CNN–LSTM model was developed to identify PM-sensitive patients and predict exacerbations. After model construction, 109 participants entered the intervention phase and were allocated to three groups (model-based intervention, forecast-based intervention, or no intervention) through initial screening and model-based grouping. The model-based group received individualized alerts with behavioral recommendations based on DL predictions, while the forecast-based group received the same recommendations based on regional air quality forecasts. The primary outcome was change in asthma exacerbation rates (measured by Intervention Effectiveness Ratio, IER). RESULTS The model-based group demonstrated significant reductions in exacerbation rates (median IER decrease: 6.6%; mean IER decrease: 11.5%; P < 0.05), whereas no significant changes were observed in the other groups. Odds ratio analysis indicated that the model-based group had 5.92- and 4.22-fold lower odds of PM2.5-related exacerbations compared with the no-intervention and forecast-based groups, respectively. Stratified and adjusted analyses confirmed that the benefit of model-based alerts remained robust despite baseline differences in asthma severity and control status. CONCLUSIONS This pilot study demonstrates the feasibility and potential effectiveness of an mHealth intervention that integrates personal PM monitoring, DL–based prediction and tailored behavioral recommendations in pediatric asthma. This approach shows promise for reducing PM-related exacerbations and warrants validation in larger, longer-term studies. CLINICALTRIAL The Clinical Research Information Service KCT0010530; https://cris.nih.go.kr/cris/search/detailSearch.do?seq=30032&search_page=L